Icomas (Methane, Acetylene, Carbon Monoxide)

Methane is an inert hydrocarbon gas that does not bind to specific human receptors. When inhaled, it can dilute oxygen in the airway, potentially leading to hypoxic effects at high concentrations. Its pharmacological activity is not defined, and any physiological impact is largely related to physical displacement of oxygen rather than a targeted biochemical mechanism.

The dosage of Icomas is determined by the prescribing healthcare professional based on the specific clinical context, if any. Because the product does not have an established therapeutic dose, prescribers must define the amount, concentration and duration of inhalation according to local regulations and safety guidelines.

There is no safety data for Icomas in pregnant or lactating individuals. The constituent gases, especially carbon monoxide, can cross the placenta and be secreted in breast milk, posing potential risks to the fetus or infant. Until reliable studies are available, use is not recommended in these populations.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements) and required import documentation.

Unlike conventional inhaled medicines such as bronchodilators or corticosteroids, Icomas contains inorganic gases without a defined therapeutic target. Established inhaled therapies act on specific receptors to relieve airway obstruction or inflammation, whereas Icomas lacks such pharmacodynamic properties and is not approved for medical treatment.

Icomas should be stored at ambient temperature, away from direct sunlight, heat sources and open flames. Keep the container tightly sealed in its original packaging to prevent gas leakage. Ensure the storage area is well‑ventilated and that personnel handling the product wear appropriate protective equipment.

Icomas is supplied as an inhalation product intended for delivery via a calibrated gas‑delivery system. Administration involves controlled release of the gas mixture into the breathing circuit under professional supervision, with continuous monitoring of the patient’s respiratory status and ambient oxygen levels.

The most serious risks stem from carbon monoxide toxicity, which can cause headache, nausea, loss of consciousness, and potentially fatal hypoxia. High concentrations of the gas mixture may also lead to severe respiratory irritation, pulmonary edema, and cardiac arrhythmias, especially in vulnerable individuals.

Icomas should not be used by individuals with known respiratory disorders, cardiovascular disease, or any condition that predisposes them to hypoxia. It is also contraindicated for pregnant or breastfeeding persons, children, and anyone lacking professional medical supervision during exposure.